WASHINGTON, October 21, 2026 – At 8:15 AM on a rainy Thursday in London, 47-year-old Sarah sat in her car outside the office, her hands trembling over the steering wheel. She wasn’t facing a sudden corporate crisis; she was experiencing debilitating brain fog, night sweats, and severe anxiety that her doctor had brushed off as simple workplace stress.
By noon, she had quietly drafted her resignation.
Sarah’s case is not unique but rather part of an economic hemorrhage. Across the world, millions of women in mid-career are abandoning prime executive and leadership positions merely because midlife hormonal wellness is a huge blind spot in primary care.
Whenever healthcare systems turn a blind eye to perimenopause, Premenstrual Dysphoric Disorder (PMDD), and hormonal transitions, national economies suffer almost instantly. Productive employees leave at the very moment they are most productive and knowledgeable about their workplaces.
According to activists such as Dr. Louise Newson, women’s hormonal wellness continues to be underplayed in mainstream medicine. This means that women get piecemeal treatment for sleep, mood, and anxiety without being assessed for perimenopause or PMDD.
The cost is hard to ignore. When experienced workers reduce hours, take extended leave, or leave jobs altogether because their symptoms are dismissed, employers lose institutional knowledge and health systems inherit more complex, delayed care. The precise global cost varies by country and methodology, but the direction is clear: untreated midlife hormonal health is a workforce problem, not merely a private medical one.
Educational programs such as Balance seek to address this problem through the provision of evidence-based healthcare information and digital tools that assist women in dealing with perimenopause and menopause.
But why does this matter? Because in many labor markets, women aged 45 to 55 are becoming a more prominent presence in the workforce.
The psychological impact is just as dramatic. Hormonal imbalances that occur during perimenopause lead to serious depression and panic attacks, which are often mistaken for psychiatric illnesses. In the absence of any guidelines from general practitioners on hormonal psychological issues, patients suffer months of unsuccessful treatment.
So why does this institutional neglect persist?
It is partly due to cultural silence, but more so to policy inaction, because clinical practice guidelines in various nations have failed to update in accordance with current research on endocrinology, leaving primary physicians ill-prepared for identifying early symptoms of perimenopause and differentiating between PMDD and mood disorders.
The consequences reach well beyond individual families. Companies are losing experienced employees, while healthcare services are squandering their money on the wrong treatment, and national budgets are deprived of contributions from qualified individuals.
Overlooking hormones during middle age is not merely neglecting women’s health anymore; it’s ignoring macroeconomic issues. Until clinical practice guidelines adapt to the current state of affairs, nations will continue losing experienced professionals who quietly resign.
